BRPI0921424A2 - vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica. - Google Patents
vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica.Info
- Publication number
- BRPI0921424A2 BRPI0921424A2 BRPI0921424A BRPI0921424A BRPI0921424A2 BR PI0921424 A2 BRPI0921424 A2 BR PI0921424A2 BR PI0921424 A BRPI0921424 A BR PI0921424A BR PI0921424 A BRPI0921424 A BR PI0921424A BR PI0921424 A2 BRPI0921424 A2 BR PI0921424A2
- Authority
- BR
- Brazil
- Prior art keywords
- attenuated
- rsv
- immunogenic composition
- population
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18564—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19832708P | 2008-11-05 | 2008-11-05 | |
PCT/US2009/063024 WO2010053883A1 (en) | 2008-11-05 | 2009-11-03 | Live, attentuated respiratory syncytial virus |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0921424A2 true BRPI0921424A2 (pt) | 2016-01-05 |
Family
ID=41527812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921424A BRPI0921424A2 (pt) | 2008-11-05 | 2009-11-03 | vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica. |
Country Status (19)
Country | Link |
---|---|
US (1) | US9011876B2 (pt) |
EP (1) | EP2346990B1 (pt) |
JP (2) | JP5016731B2 (pt) |
KR (1) | KR20110063863A (pt) |
CN (1) | CN102272295A (pt) |
AU (1) | AU2009311287C1 (pt) |
BR (1) | BRPI0921424A2 (pt) |
CA (1) | CA2742086A1 (pt) |
CL (1) | CL2011000999A1 (pt) |
CO (1) | CO6362047A2 (pt) |
EC (1) | ECSP11011033A (pt) |
IL (1) | IL212437A0 (pt) |
MA (1) | MA32878B1 (pt) |
MX (1) | MX2011004719A (pt) |
PE (1) | PE20110394A1 (pt) |
RU (1) | RU2011122615A (pt) |
TN (1) | TN2011000182A1 (pt) |
WO (1) | WO2010053883A1 (pt) |
ZA (1) | ZA201103259B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110063863A (ko) * | 2008-11-05 | 2011-06-14 | 머크 샤프 앤드 돔 코포레이션 | 생 약독화 호흡기 세포융합 바이러스 |
WO2013026054A2 (en) * | 2011-08-18 | 2013-02-21 | Axella Solutions, Llc | Production of infectious rna viruses in yeast |
WO2013031827A1 (ja) | 2011-08-29 | 2013-03-07 | 国立大学法人徳島大学 | Rsv粘膜ワクチン |
EP4190895A1 (en) * | 2013-02-08 | 2023-06-07 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization |
PL2970981T3 (pl) * | 2013-03-14 | 2021-07-05 | Emory University | Rekombinowany RSV z cichymi mutacjami, szczepionki i związane z nimi sposoby |
US10429129B2 (en) | 2013-10-16 | 2019-10-01 | Merck Sharp & Dohme Corp. | Method of microwave vacuum drying spherical-shaped pellets of biological materials |
EP3057611A4 (en) | 2013-10-16 | 2017-04-12 | Merck Sharp & Dohme Corp. | Thermostable respiratory synctial virus (rsv) vaccine compositions |
US10947512B2 (en) * | 2015-08-14 | 2021-03-16 | Research Institute At Nationwide Children's Hospital | Respiratory syncytial virus having altered NS1 protein function and related materials and methods |
SG11201803581VA (en) | 2015-10-29 | 2018-05-30 | Univ Emory | Chimeric RSV, Immunogenic Compositions, and Methods of Use |
US10808012B2 (en) | 2016-09-23 | 2020-10-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes |
TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
KR20200096904A (ko) * | 2017-09-15 | 2020-08-14 | 오하이오 스테이트 이노베이션 파운데이션 | 호흡기 세포융합 바이러스(rsv) 감염의 예방을 위한 백신 및 백신의 제조 및 사용 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2250883A1 (en) | 1996-04-04 | 1997-10-16 | The Regents Of The University Of Michigan | Attenuated respiratory syncytial virus |
BR9909076A (pt) | 1998-03-26 | 2000-12-05 | American Cyanamid Co | Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b |
KR100905450B1 (ko) | 1999-07-09 | 2009-07-02 | 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 | 약독화된 인간-소 키메릭 호흡기 신시티움 바이러스백신의 제조 방법 |
WO2004028478A2 (en) | 2002-09-27 | 2004-04-08 | Medimmune Vaccines, Inc. | Functional mutations in respiratory syncytial virus |
WO2004087062A2 (en) * | 2003-03-28 | 2004-10-14 | Medimmune Vaccines, Inc. | Compositions and methods involving respiratory syncytial virus subgroup b strain 9320 |
WO2008096811A1 (ja) * | 2007-02-07 | 2008-08-14 | Dnavec Corporation | 弱毒化マイナス鎖rnaウイルス |
KR20110063863A (ko) * | 2008-11-05 | 2011-06-14 | 머크 샤프 앤드 돔 코포레이션 | 생 약독화 호흡기 세포융합 바이러스 |
-
2009
- 2009-11-03 KR KR1020117010304A patent/KR20110063863A/ko not_active Application Discontinuation
- 2009-11-03 MX MX2011004719A patent/MX2011004719A/es unknown
- 2009-11-03 PE PE2011000971A patent/PE20110394A1/es not_active Application Discontinuation
- 2009-11-03 EP EP09748199.8A patent/EP2346990B1/en active Active
- 2009-11-03 RU RU2011122615/10A patent/RU2011122615A/ru not_active Application Discontinuation
- 2009-11-03 BR BRPI0921424A patent/BRPI0921424A2/pt not_active IP Right Cessation
- 2009-11-03 US US13/127,647 patent/US9011876B2/en active Active
- 2009-11-03 CA CA2742086A patent/CA2742086A1/en not_active Abandoned
- 2009-11-03 JP JP2011534864A patent/JP5016731B2/ja not_active Expired - Fee Related
- 2009-11-03 AU AU2009311287A patent/AU2009311287C1/en not_active Ceased
- 2009-11-03 CN CN2009801537266A patent/CN102272295A/zh active Pending
- 2009-11-03 WO PCT/US2009/063024 patent/WO2010053883A1/en active Application Filing
-
2011
- 2011-04-17 IL IL212437A patent/IL212437A0/en unknown
- 2011-04-19 TN TN2011000182A patent/TN2011000182A1/fr unknown
- 2011-05-04 CL CL2011000999A patent/CL2011000999A1/es unknown
- 2011-05-05 EC EC2011011033A patent/ECSP11011033A/es unknown
- 2011-05-05 ZA ZA2011/03259A patent/ZA201103259B/en unknown
- 2011-05-12 CO CO11058596A patent/CO6362047A2/es not_active Application Discontinuation
- 2011-06-03 MA MA33913A patent/MA32878B1/fr unknown
- 2011-08-05 JP JP2011171459A patent/JP5743794B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MA32878B1 (fr) | 2011-12-01 |
US20110212130A1 (en) | 2011-09-01 |
EP2346990B1 (en) | 2016-01-06 |
ECSP11011033A (es) | 2011-12-30 |
CO6362047A2 (es) | 2012-01-20 |
US9011876B2 (en) | 2015-04-21 |
TN2011000182A1 (en) | 2012-12-17 |
WO2010053883A1 (en) | 2010-05-14 |
JP2011250798A (ja) | 2011-12-15 |
RU2011122615A (ru) | 2012-12-20 |
AU2009311287A1 (en) | 2010-05-14 |
JP5743794B2 (ja) | 2015-07-01 |
CL2011000999A1 (es) | 2012-07-20 |
CN102272295A (zh) | 2011-12-07 |
ZA201103259B (en) | 2012-01-25 |
KR20110063863A (ko) | 2011-06-14 |
JP2012507302A (ja) | 2012-03-29 |
JP5016731B2 (ja) | 2012-09-05 |
AU2009311287B2 (en) | 2013-02-07 |
PE20110394A1 (es) | 2011-06-22 |
AU2009311287C1 (en) | 2015-02-19 |
MX2011004719A (es) | 2011-05-31 |
CA2742086A1 (en) | 2010-05-14 |
EP2346990A1 (en) | 2011-07-27 |
IL212437A0 (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0921424A2 (pt) | vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica. | |
WO2017070626A3 (en) | Respiratory virus vaccines | |
CY1117673T1 (el) | Ανασυνδυασμενα αντιγονα rsv | |
BRPI1013394A2 (pt) | "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c." | |
EA201491754A1 (ru) | Вакцина против rsv | |
WO2011005799A3 (en) | Rna containing modified nucleotides and use thereof in vaccines | |
BRPI0905663A2 (pt) | "emulsão estável, processo de preparação da emulsão estável e uso emulsão" | |
AR096113A1 (es) | Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados | |
BRPI0816330A2 (pt) | Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina | |
BRPI0814899A2 (pt) | Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo" | |
BRPI0916235A2 (pt) | composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv | |
BRPI0814939A2 (pt) | Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero. | |
BRPI0717219A2 (pt) | "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica." | |
EA201070794A1 (ru) | Рекомбинантные антигены rsv | |
CA2746228C (en) | Modified rsv f proteins and methods of their use | |
BRPI0820576A2 (pt) | "vírus da varíola, processo para preparar o mesmo, composição, uso de um vírus da varíola uo uma composição, e método para tratar doenças" | |
BRPI0920026A2 (pt) | método de tratamento de infecção pulmonar, composição farmacêutica e respectivos usos. | |
BRPI0716145A2 (pt) | formuaÇço de vacina, mÉtodo de adaptaÇço e propagaÇço do vÍrus chikungunya, mÉtodo de concentraÇço e purificaÇço de vÍrus, composiÇço potencialmente imunogÊnica, sequÊncia de nucleotÍdeo, contruto de dna recombinante, mÉtodo para produzir proteÍna recombinante, composiÇço farmacÊutica, mÉtodo in vitro ou in vivo e mÉtodo para elicitar resposta imune protetora | |
BRPI1014800A8 (pt) | "composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas" | |
BR112012002603A2 (pt) | composição imunogênica, proteína de fusão, polinucleotídeo, vacina, processo para preparar a vacina, uso da composição imunogênica, e, método para tratar ou prevenir doença estafilocócica. | |
WO2007002470A3 (en) | Inactivated chimeric vaccines and related methods of use | |
WO2008156778A3 (en) | Influenza m2 protein mutant viruses as live influenza attenuated vaccines | |
IT1402907B1 (it) | Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose. | |
WO2011094357A8 (en) | Respiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization | |
WO2014049447A3 (en) | A whole, leech saliva extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: SCHERING CORPORATION (US) |
|
B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2376 DE 19-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |